Farms.com Home   News

Canadian biochar firm raises €35.5m in funding round

Airex Energy has raised $38 million (€35.5m) in a funding round that will accelerate the Quebec company’s plans to expand its production of low-carbon industrial and agricultural products made from biomass, reported the Globe and Mail.

The seven-year-old company employs its own technology to turn sawmill byproducts and logging residue into biocoal pellets at its plant in Bécancour, Quebec. Biocoal can replace coal in power plants, slashing greenhouse-gas emissions by 90%, according to Airex.

The financing is led by Cycle Capital and includes existing investors Investissement Québec, Desjardins-Innovatech and Export Development Canada. A new investor, Fonds de solidarité FTQ, joined the group in the funding round.

It also has a recently renewed partnership with France’s Suez Group to develop markets for biochar, which is used as an additive in soil, and can also sequester carbon if processed into building materials such as concrete.
Airex will use proceeds from the funding round to increase capacity at its commercial-scale Bécancour biocoal plant, Michel Gagnon, the company’s chief executive, said in an interview.

Click here to see more...

Trending Video

Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Video: Finding a Balance of Innovation and Regulation - Dr. Peter Facchini

Regulations help markets and industry exist on level playing fields, keeping consumers safe and innovation from going too far. However, incredibly strict regulations can stunt innovation and cause entire industries to wither away. Dr. Peter James Facchini brings his perspective on how existing regulations have slowed the advancement of medical developments within Canada. Given the international concern of opium poppy’s illicit potential, Health Canada must abide by this global policy. But with modern technology pushing the development of many pharmaceuticals to being grown via fermentation, is it time to reconsider the rules?

Dr. Peter James Facchini leads research into the metabolic biochemistry in opium poppy at the University of Calgary. For more than 30 years, his work has contributed to the increased availability of benzylisoquinoline alkaloid biosynthetic genes to assist in the creation of morphine for pharmaceutical use. Dr. Facchini completed his B.Sc. and Ph.D. in Biological Sciences at the University of Toronto before completing Postdoctoral Fellowships in Biochemistry at the University of Kentucky in 1992 & Université de Montréal in 1995.